市場調查報告書
商品編碼
1411270
胱抑素 C 測定市場 - 依產品(試劑盒、試劑、分析儀)、依樣本種類(血液、尿液)、依方法(ELISA、PETIA、PENIA、CLIA、免疫螢光測定)、按應用、最終用途與預測,2024-2032 年Cystatin C Assay Market - By Product (Kits, Reagents, Analyzers), By Sample Type (Blood, Urine), By Method (ELISA, PETIA, PENIA, CLIA, Immunofluorescence Assay), By Application, End use & Forecast, 2024-2032 |
預計從 2024 年到 2032 年,胱抑素 C 檢測行業規模將以超過 7.7% 的CAGR擴大。全球慢性腎臟病(CKD) 患病率不斷上升,加上人口老齡化,正在推動對準確和早期診斷工具(例如胱抑素)的需求C 測定。
最近,人們越來越認知到肌酸酐等傳統生物標記在檢測早期腎功能障礙方面的局限性。技術的不斷進步導致了更靈敏和更特異的檢測方法的開發。例如,2022 年 8 月,瑞士醫療科技公司 Bloom Diagnostics 推出了 Bloom Kidney Test,旨在量化全血中的胱抑素 C。對預防性醫療保健的日益重視以及醫療保健系統中創新診斷解決方案的整合也將推動市場擴張。
胱抑素 C 檢測市場分為產品、樣品類型、方法、應用、最終用途和地區。
就產品而言,由於慢性腎臟病患病率不斷上升,對可靠診斷工具的需求不斷增加,預計2024年至2032年試劑領域的產業價值將以7.7%的CAGR成長。試劑技術的不斷進步正在提高準確性和靈敏度。此外,人們日益認知到傳統生物標記的限制將促進該領域的成長。
胱抑素 C 檢測市場的尿液樣本部分預計在 2024 年至 2032 年間複合CAGR為7.5%。這一成長可歸因於對精確腎功能評估的需求增加以及人們對基於尿液的胱抑素C 檢測優勢的認知不斷提高。此外,腎臟疾病發生率的上升將進一步推動尿液採樣的採用。
從地區來看,2024 年至 2032 年,歐洲胱抑素 C 檢測行業規模預計將以 7.8% 的CAGR擴大。這一成長可歸因於慢性腎病病例激增、人口迅速老化以及先進診斷技術的日益採用。此外,對醫療基礎設施發展和預防醫學的高度重視將推動區域市場的擴張。
Cystatin C assay industry size is projected to expand at over 7.7% CAGR from 2024 to 2032. The rising prevalence of chronic kidney diseases (CKDs) globally, coupled with the aging population is driving the demand for accurate and early diagnostic tools, such as cystatin C assays.
Of late, there has been growing awareness about the limitations of traditional biomarkers like creatinine in detecting early-stage kidney dysfunctions. The increasing technological advancements are leading to the development of more sensitive and specific assays. For instance, in August 2022, Bloom Diagnostics, a Swiss MedTech company, launched Bloom Kidney Test, designed for quantifying cystatin C in whole blood. The surging emphasis on preventive healthcare and the integration of innovative diagnostic solutions in healthcare systems will also fuel the market expansion.
The cystatin C assay market is segregated into product, sample type, method, application, end-use, and region.
In terms of product, the industry value from the reagents segment is estimated to rise at 7.7% CAGR from 2024 to 2032, owing to the increasing demand for reliable diagnostic tools due to the rising prevalence of chronic kidney diseases. The ongoing advancements in reagent technology is leading to enhanced accuracy and sensitivity. Additionally, the growing awareness of the limitations of traditional biomarkers will boost the segment growth.
The urine sample segment of the cystatin C assay market is estimated to depict 7.5% CAGR between 2024 and 2032. The growth can be attributed to the heightened demand for precise kidney function assessment and the increasing awareness of the advantages of urine-based cystatin C testing. Moreover, the higher incidences of renal disorders will further drive the adoption of urine sampling.
Regionally, the Europe cystatin C assay industry size is projected to expand at 7.8% CAGR from 2024 to 2032. The growth can be attributed to the surge in chronic kidney disease cases, rapidly aging population, and the increasing adoption of advanced diagnostic technologies. Additionally, the high emphasis on healthcare infrastructure development and preventive medicine will drive the regional market expansion.